The Value of Neuraminidase Inhibitors for the Prevention and Treatment of Seasonal Influenza: A Systematic Review of Systematic Reviews

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Michiels, Barbara ^a   van Puyenbroeck, Karolien ^a   Verhoeven, Veronique ^a   Vermeire, Etienne ^a   Coenen, Samuel ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIBIOTIC AGENT; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; PLACEBO; SIALIDASE INHIBITOR; ZANAMIVIR;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ASTHMA; BRONCHITIS; CHILD; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HOSPITALIZATION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MORTALITY; NAUSEA; OTITIS MEDIA; OUTCOME ASSESSMENT; PNEUMONIA; POST EXPOSURE PROPHYLAXIS; REVIEW; RISK REDUCTION; SEASONAL INFLUENZA; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); UNSPECIFIED SIDE EFFECT; VOMITING;

ANTIBIOTIC PROPHYLAXIS; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE; OSELTAMIVIR; TREATMENT OUTCOME; ZANAMIVIR;

EID: 84875648078     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060348     Document Type: Review

References (119)

1. Moscona A, (2005) Neuraminidase inhibitors for influenza. N Engl J Med 353: 1363-1373.
2. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, et al. (2010) Vaccines for preventing influenza in the elderly. Cochrane Database of Systematic Reviews: CD004876.
3. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, et al. (2010) Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews: CD001269.
4. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V (2008) Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews: CD004879.
5. Michiels B, Govaerts F, Remmen R, Vermeire E, Coenen S, (2011) A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine 29: 9159-9170.
6. Adriaenssens N, Coenen S, Kroes AC, Versporten A, Vankerckhoven V, et al. (2011) European Surveillance of Antimicrobial Consumption (ESAC): systemic antiviral use in Europe. J Antimicrob Chemother 66: 1897-1905.
7. Kawai N, Ikematsu H, Tanaka O, Matsuura S, Maeda T, et al. (2011) Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007-2008 and 2008-2009 seasons. J Infect Chemother 17: 375-381.
8. Burch J, Paulden M, Conti S, Stock C, Corbett M, et al. (2009) Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess 13: 1-265.
9. Cohen D, (2009) Complications: tracking down the data on oseltamivir. BMJ 339: b5387.
10. Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, et al. (2012) Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database of Systematic Reviews: CD008965.
11. Doshi P, (2009) Neuraminidase inhibitors-the story behind the Cochrane review. BMJ 339: b5164.
12. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, et al. (2003) Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 163: 1667-1672.
13. Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, et al. (2009) AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 62: 1013-1020.
14. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, et al. (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64: 383-394.
15. Higgins JPT, Green S (editors) (2009) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration. Available: www.cochrane-handbook.org.
16. Jagannath VA, Asokan GV, Fedorowicz Z, Singaram JS, Lee TW, (2010) Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. Cochrane Database of Systematic Reviews 3: CD008139.
17. Wang K, Shun-Shin M, Gill P, Perera R, Harnden A (2012) Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Cochrane Database of Systematic Reviews: CD002744.
18. Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, et al. (2009) Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. Health Technol Assess 13: iii, ix-xii, 1-246.
19. Deonandan R (2006) Oseltamivir and Zanamivir for the Prevention of influenza. Canadian Agency for Drugs and Technologies in Health.
20. Falagas ME, Koletsi PK, Vouloumanou EK, Rafailidis PI, Kapaskelis AM, et al. (2010) Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials J Antimicrob Chemother. 65: 1330-1346.
21. Jackson RJ, Cooper KL, Tappenden P, Rees A, Simpson EL, et al. (2011) Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. J Infect 62: 14-25.
22. Khazeni N, Bravata DM, Holty JE, Uyeki TM, Stave CD, et al. (2009) Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Ann Intern Med 151: 464-473.
23. Burch J, Corbett M, Stock C, Nicholson K, Elliot AJ, et al. (2009) Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. Lancet Infect Dis 9: 537-545.
24. Deng WW, Li QY, Zhong NS, (2004) [A multicenter study of efficacy and safety of oseltamivir in the treatment of suspected influenza patients] Zhonghua Yi Xue Za Zhi. 84: 2132-2136.
25. Lin JT, Yu XZ, Cui DJ, Chen XY, Zhu JH, et al. (2004) [A multicenter randomized controlled study of the efficacy and safety of oseltamivir in the treatment of influenza in a high risk population]. Zhonghua Jie He He Hu Xi Za Zhi 27: 455-459.
26. Hayden FG, Belshe R, Villanueva C, Lanno R, Hughes C, et al. (2004) Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 189: 440-449.
27. LaForce C, Man CY, Henderson FW, McElhaney JE, Hampel FC Jr, et al. (2007) Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 29: 1579-1590.
28. Ambrozaitis A, Gravenstein S, van Essen GA, Rubinstein E, Balciuniene L, et al. (2005) Inhaled Zanamivir Versus Placebo for the Prevention of Influenza Outbreaks in an Unvaccinated Long-term Care Population. J Am Med Dir Assoc 6: 367-374.
29. Hedrick JA, Barzilai A, Behre U, Henderson FW, Hammond J, et al. (2000) Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 19: 410-417.
30. Monto AS, Robinson DP, Herlocher ML, Hinson JM, et al. (1999) Zanamivir in the prevention of influenza among healthy adults- a randomized controlled trial. JAMA 282: 31-35.
31. Lalezari J, Campion K, Keene O, Silagy C, (2001) Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 16: 212-217.
32. Doshi P, Jones M, Jefferson T, (2012) Rethinking credible evidence synthesis. BMJ 344: d7898.
33. Ebell MH, Call M, Shinholser J (2012) Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials. Fam Pract Sep 20.
34. Hernán MA, Lipsitch M, (2011) Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 53: 277-279.
35. Cochrane Neuraminidase Inhibitors Review Team (2011) Does oseltamivir really reduce complications of influenza? Clin Infect Dis 53: 1302-1303.
36. Hernán MA, Lipsitch M, (2011) Reply to Cochrane Neuraminidase Inhibitors Review Team. Clin Infect Dis 53: 1303-1304.
37. Harper SA, Englund JA, File TM, Gravenstein S, Hayden FG, et al. (2009) Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 48: 1003-1032.
38. NHG Standaard [Practice guideline] (2008) Influenza en influenzavaccinatie [Influenza and influenza vaccination] M35 NHG- Nederlands Huisartsen Genootschap [The Dutch College of General Practitioners].
39. NICE (2008) NICE technology appraisal guidance 158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (Includes a review of NICE technology appraisal guidance 67) London.
40. NICE (2009) Amantadine, oseltamivir and zanamivir for the treatment of influenza TA-168(Structured abstract). National Institute for Health and Clinical Excellence: HTA-32011000098.
41. Van de Vyver N, Janssens W, De Sutter A, Michiels B, Govaerts F, et al. (2006) Antivirale middelen bij seizoensgriep en grieppandemie. Literatuurstudie en ontwikkeling van praktijkrichtlijnen. [Antiviral agents in seasonal and pandemic influenza. Literature study and development of practice guidelines]. Brussel: Federaal Kenniscentrum voor de gezondheidszorg [The Belgian Health Care Knowledge Centre] (KCE). KCE reports 49 A (D/2006/2010.2273/2065) p.
42. Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, et al. (2001) Effectiveness of oseltamivir in preventing influenza in household contacts: a randomised controlled trial. JAMA 285: 748-754.
43. Jefferson T, Del Mar CB, Dooley L, Ferroni E, Al-Ansary LA, et al. (2011) Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database of Systematic Reviews: CD006207.
44. Lee VJ, Lye DC, Wilder-Smith A, (2009) Combination strategies for pandemic influenza response- a systematic review of mathematical modeling studies. BMC Med 7: 76.
45. Thorlund K, Awad T, Boivin G, Thabane L, (2011) Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 11: 134.
46. Sugaya N, Ohashi Y, (2010) Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 54: 2575-2582.
47. Kashiwagi S, Kudoh S, Watanabe A, Yoshimura I, (2000) [Efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir for prophylaxis against influenza-placebo-controlled double-blind multicenter phase III trial]. Kansenshogaku Zasshi 74: 1062-1076.
48. Michiels B, Thomas I, Van Royen P, Coenen S, (2011) Clinical prediction rules combining signs, symptoms and epidemiological context to distinguish influenza from influenza-like illnesses in primary care: a cross sectional study. BMC Family Practice 12: 4.
49. Beigel J, Bray M, (2008) Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 78: 91-102.
50. Bettis R, Iacuzio D, Jung T, Fuchs R, Aultman R, et al. (2006) Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise healthy adults and adolescents. Clin Drug Investig 26: 329-340.
51. Bijl D, (2011) Pandemic influenza vaccines and neuraminidase inhibitors: efficacy and side effects. Int J Risk Saf Med 23: 65-71.
52. Chidiac C, (2008) [Influenza]. Rev Prat 58: 445-453.
53. Clark NM, Lynch JP, (2011) Influenza: epidemiology, clinical features, therapy, and prevention. Semin Respir Crit Care Med 32: 373-392.
54. Dutkowski R, (2010) Oseltamivir in seasonal influenza: cumulative experience in low-and high-risk patients. J Antimicrob Chemother 65: ii11-ii24.
55. Ferraris O, Escuret V, Bouscambert-Duchamp M, Lina B, Morfin F, (2010) [Role of neuraminidase inhibitors for the treatment of influenza A virus infections]. Pathol Biol (Paris) 58: e69-78.
56. Freemantle N, Calvert M, (2009) What can we learn from observational studies of oseltamivir to treat influenza in healthy adults? BMJ 339: b5248.
57. Health Technology Assessment (2010) Systematic review and economic modelling of the use of neuraminidase inhibitors for the prevention and treatment of influenza A and B (Structured abstract). Health Technology Assessment: HTA-32010000424.
58. Heneghan CJ (2011) Update and amalgamation of two Cochrane Reviews: neuraminidase inhibitors for preventing and treating influenza in healthy adults and children (project record). NIHR Health Technology Assessment programme: HTA-32011001126.
59. Holzgrabe U, (2011) [How safe was oseltamivir care in the flu pandemic?]. Pharm Unserer Zeit 40: 151-154.
60. Jamieson B, Jain R, Carleton B, Goldman RD, (2009) Use of oseltamivir in children. Can Fam Physician 55: 1199-1201.
61. Jefferson T, Demicheli V, Di Pietrantonj C, Jones M, Rivetti D (2006) Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database of Systematic Reviews: CD001265.
62. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, et al. (2006) Antivirals for influenza in healthy adults: systematic review. Lancet 367: 303-313.
63. Jefferson T, Jones M, Doshi P, Del Mar C, (2009) Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 339: b5106.
64. Jefferson T, Jones M, Doshi P, Del Mar C, Dooley L, et al. (2010) Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database of Systematic Reviews: CD001265.
65. Jefferson T, Jones M, Doshi P, Del Mar C, Dooley L, et al. (2010) Neuraminidase inhibitors for preventing and treating influenza in healthy adults: a Cochrane review. Health Technol Assess 14: 355-458.
66. Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, et al. (2011) Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children- a review of clinical study reports (protocol). Cochrane Database of Systematic Reviews: 1.
67. Jones M, Del Mar C, (2006) Safety of neuraminidase inhibitors for influenza. Expert Opin Drug Saf 5: 603-608.
68. Klebe G, Schlitzer M, (2011) [M2 inhibitors and neuraminidase inhibitors]. Pharm Unserer Zeit 40: 144-150.
69. Lee N, Ison MG, (2012) Diagnosis, management and outcomes of adults hospitalized with influenza. Antivir Ther 17: 143-157.
70. Lynch JP, Walsh EE, (2007) Influenza: evolving strategies in treatment and prevention. Semin Respir Crit Care Med 28: 144-158.
71. Mallia P, Johnston SL, (2007) Influenza infection and COPD. Int J Chron Obstruct Pulmon Dis 2: 55-64.
72. Matheson NJ, Harnden AR, Perera R, Sheikh A, Symmonds-Abrahams M (2007) Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database of Systematic Reviews: CD002744.
73. McCullers JA, (2011) Preventing and treating secondary bacterial infections with antiviral agents. Antivir Ther 16: 123-135.
74. Moscona A, (2008) Medical management of influenza infection. Annu Rev Med 59: 397-413.
75. NICE (2008) Oseltamivir, amantadine and zanamivir for the prophylaxis of influenza (including a review of TA67) (Structured abstract). National Institute for Health and Clinical Excellence: HTA-32011000382.
76. Nayak JL, Treanor JJ, (2009) Antiviral treatment and prophylaxis of influenza virus in children. Pediatr Ann 38: 667-674.
77. Antiviral drugs prophylaxis and treatment of influenza. Review. Med Lett Drugs Ther 48: 87-88.
78. Antiviral drugs for influenza. Review. Med Lett Drugs Ther 51: 89-92.
79. Antiviral drugs for influenza. Review. Med Lett Drugs Ther 54: 1-3.
80. Nüesch R, (2007) [Antiviral treatment of influenza in humans]. Ther Umsch 64: 635-641.
81. Oxford JS, (2007) Antivirals for the treatment and prevention of epidemic and pandemic influenza. Influenza Other Respi Viruses 1: 27-34.
82. Preziosi P, (2011) Influenza pharmacotherapy: present situation, strategies and hopes. Expert Opin Pharmacother 12: 1523-1549.
83. Ruf BR, Sandow P, Lehmann P, Del Piero L, Skopnik H, (2008) [Significance of the neuraminidase inhibitor oseltamivir for the management of seasonal influenza]. Dtsch Med Wochenschr 133: 1259-1264.
84. Ruf BR, Szucs T, (2009) Reducing the burden of influenza-associated complications with antiviral therapy. Infection Control & Hospital Epidemiology 37: 186-196.
85. Salzberger B, (2006) [Antiviral therapy: from influenza to Pfeiffer's disease]. Internist (Berl) 47: 1245-1250.
86. Schirmer P, (2009) Holodniy M. Oseltamivir for treatment and prophylaxis of influenza infection. Expert Opin Drug Saf 8: 357-371.
87. Shun-Shin M, Thompson M, Heneghan C, Perera R, Harnden A, et al. (2009) Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. BMJ 339: b3172.
88. Smith JR, Rayner CR, Donner B, Wollenhaupt M, Klumpp K, et al. (2011) Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience. Adv Ther 28: 927-959.
89. Tambyah PA, (2008) Update on influenza anti-virals. Respirology 13 (Suppl 1):: S19-21.
90. Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, et al. (2009) Zanamivir, oseltamivir and amantadine for the treatment of influenza (an update review of existing guidance) (Structured abstract). Health Technology Assessment: HTA-32008100360.
91. Toovey S, Rayner C, Prinssen E, Chu T, Donner B, et al. (2008) Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 31: 1097-1114.
92. Townsend KA, Eiland LS, (2006) Combating influenza with antiviral therapy in the pediatric population. Pharmacotherapy 26: 95-103.
93. Tullu MS, (2009) Oseltamivir. J Postgrad Med 55: 225-230.
94. Wang K, Shun-Shin M, Gill P, Perera R, Harnden A (2012) Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database of Systematic Reviews: CD002744.
95. Wesseling G, (2007) Occasional review: influenza in COPD: pathogenesis, prevention, and treatment. Int J Chron Obstruct Pulmon Dis 2: 5-10.
96. Whitley RJ, (2007) The role of oseltamivir in the treatment and prevention of influenza in children. Expert Opin Drug Metab Toxicol 3: 755-767.
97. Yang Ming, Dong Bi Rong, Wu Hong Mei, Li Ting, Liu Guan J (2010) Interventions for treating influenza: an overview of Cochrane systematic reviews. Cochrane Database of Systematic Reviews: Protocols: CD008799.
98. Yang Ming, Wu Hong Mei, Li Ting, Dong Bi Rong, Liu Guan J (2010) Interventions for preventing influenza: an overview of Cochrane systematic reviews. Cochrane Database of Systematic Reviews: Protocols: CD008501.
99. Hayden FG, Atmar RL, SchillingM, Johnson C, Poretz D, et al. (1999) Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 341: 1336-1343.
100. Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliott MJ, et al. (2000) Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 343: 1282-1289.
101. Monto AS, Pichichero ME, Blanckenberg SJ, Ruuskanen O, Cooper C, et al. (2002) Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 186: 1582-1588.
102. Kaiser L, Henry D, Flack NP, Keene O, Hayden FG, (2000) Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin Infect Dis 30: 587-589.
103. Peters PH, Gravenstein S, Norwood P, De Bock V, Van Couter A, et al. (2001) Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 49: 1025-1031.
104. Li L, Cai B, Wang M, Zhu Y, (2003) A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China. Chin Med J (Engl) 116: 44-48.
105. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, et al. (2000) Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355: 1845-1850.
106. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, et al. (2000) Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283: 1016-1024.
107. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, et al. (2001) Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20: 127-133.
108. Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, et al. (1997) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 337: 874-880.
109. Makela MJ, Pauksens K, Rostila T, DM F, Man CY, et al. (2000) Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 40: 42-48.
110. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group (1998) Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 352: 1877-1881.
111. Puhakka T, Lehti H, Vainionpaa R, Jormanainen V, Pulkkinen M, et al. (2003) Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. Scand J Infect Dis 35: 52-58.
112. Johnston SL, Ferrero F, Garcia ML, Dutkowski R, (2005) Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr Infect Dis J 24: 225-232.
113. Martin C, Mahoney P, Ward P, (2001) Oral oseltamivir reduces febrile illness in patients considered at high risk of influenza complications. Int Congr Ser 1219: 807-811.
114. Boivin G, Goyette N, Hardy I, Aoki F, Wagner A, et al. (2000) Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. J Infect Dis 181: 1471-1474.
115. Murphy KR, Eivindson A, Pauksens K, Stein WJ, Tellier G, et al. (2000) Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease: A double-blind, randomised, placebo-controlled, multicentre study. Clinical Drug Investigation 20: 337-349.
116. Tan W, Hou J, Chen X, Xiong H, Li XQ, et al. (2002) [A randomized, double-blinded and controlled clinical evaluation of oseltamivir in the treatment of influenza]. Clin Med J China 9: 528-531.
117. Matsumoto K, Ogawa N, Nerome K, Numazaki Y, Kawakami Y, et al. (1999) Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group. Antivir Ther 4: 61-68.
118. Webster A, Boyce M, Edmundson S, Miller I, (1999) Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. Clin Pharmacokinet 36 (Suppl 1):: 51-58.
119. Heinonen S, Silvennoinen H, Lehtinen P, Vainionpää R, Vahlberg T, et al. (2010) Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis 51: 887-894.